Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces Proposed Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering.
View HTML
Toggle Summary Dynavax Provides U.S. Regulatory Update on HEPLISAV-B(TM) Following FDA Advisory Committee Meeting
Conference call today at 4:30 p.m. EDT
View HTML
Toggle Summary Dynavax Reports Second Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 08/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017 . Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31,
View HTML
Toggle Summary Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B(TM)
BERKELEY, CA -- (Marketwired) -- 07/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B
View HTML
Toggle Summary Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA(R) (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy
Data Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
View HTML
Toggle Summary Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, CA -- (Marketwired) -- 05/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by
View HTML
Toggle Summary Dynavax Reports First Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 05/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2017 . Cash, cash equivalents and marketable securities were $85.4 million at March 31, 2017 compared to $81.4 million at December 31,
View HTML
Toggle Summary Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Meeting Scheduled for July 28, 2017
View HTML
Toggle Summary Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
BERKELEY, CA -- (Marketwired) -- 03/20/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 (TLR9) agonists at the 2017 American Association for Cancer Research
View HTML
Toggle Summary Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
Key outcomes for multiple programs in 2017
View HTML